STOCK TITAN

[8-K] INmune Bio Inc. Common stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Netcapital Inc. (Nasdaq: NCPL) filed an 8-K reporting that on 26 June 2025 it entered into a Horizon Software Agreement with Switzerland-based Horizon Globex GmbH. Horizon granted Netcapital a royalty-free, paid-up, non-exclusive, perpetual and irrevocable license to use Horizon’s capital-raising and secondary-trading software under the Company’s own branding in the United States.

As consideration, Netcapital will issue 500,0000 shares of its common stock (the “Horizon Shares”) to Horizon or its affiliate. The shares will be issued without registration under Sections 4(a)(2) and/or 3(a)(9) of the Securities Act, and no cash will be received by the Company.

The agreement includes standard termination rights: (i) either party may terminate after a 30-day cure period for material breach, and (ii) immediate termination is permitted upon bankruptcy, receivership, dissolution, or cessation of business of the other party. The full contract is attached as Exhibit 10.1.

This transaction gives Netcapital long-term access to a trading technology platform that could expand its service offering, but it also introduces equity dilution and execution risk should the software fail to drive revenue growth.

Netcapital Inc. (Nasdaq: NCPL) ha depositato un 8-K comunicando che il 26 giugno 2025 ha stipulato un Accordo Software Horizon con la società svizzera Horizon Globex GmbH. Horizon ha concesso a Netcapital una licenza perpetua, irrevocabile, non esclusiva, royalty-free e completamente pagata per utilizzare il software di raccolta capitali e trading secondario di Horizon con il proprio marchio negli Stati Uniti.

In cambio, Netcapital emetterà 500.000 azioni ordinarie (le “Azioni Horizon”) a favore di Horizon o di una sua affiliata. Le azioni saranno emesse senza registrazione ai sensi delle Sezioni 4(a)(2) e/o 3(a)(9) del Securities Act, e la Società non riceverà alcun pagamento in contanti.

L’accordo prevede diritti di risoluzione standard: (i) ciascuna parte può recedere dopo un periodo di 30 giorni per sanare una violazione sostanziale, e (ii) la risoluzione immediata è consentita in caso di bancarotta, amministrazione controllata, scioglimento o cessazione dell’attività dell’altra parte. Il contratto completo è allegato come Allegato 10.1.

Questa operazione garantisce a Netcapital un accesso a lungo termine a una piattaforma tecnologica di trading che potrebbe ampliare la gamma di servizi offerti, ma comporta anche un diluzione azionaria e un rischio di esecuzione nel caso in cui il software non generi crescita dei ricavi.

Netcapital Inc. (Nasdaq: NCPL) presentó un 8-K informando que el 26 de junio de 2025 firmó un Acuerdo de Software Horizon con Horizon Globex GmbH, con sede en Suiza. Horizon otorgó a Netcapital una licencia perpetua, irrevocable, no exclusiva, libre de regalías y totalmente pagada para usar el software de captación de capital y comercio secundario de Horizon bajo la marca de la Compañía en Estados Unidos.

Como contraprestación, Netcapital emitirá 500,000 acciones ordinarias (las “Acciones Horizon”) a Horizon o a una afiliada. Las acciones se emitirán sin registro conforme a las Secciones 4(a)(2) y/o 3(a)(9) de la Ley de Valores, y la Compañía no recibirá efectivo.

El acuerdo incluye derechos estándar de terminación: (i) cualquiera de las partes puede rescindir tras un período de subsanación de 30 días por incumplimiento material, y (ii) se permite la terminación inmediata en caso de quiebra, administración judicial, disolución o cese de operaciones de la otra parte. El contrato completo se adjunta como Anexo 10.1.

Esta transacción le otorga a Netcapital acceso a largo plazo a una plataforma tecnológica de trading que podría ampliar su oferta de servicios, pero también implica dilución accionaria y riesgo de ejecución si el software no impulsa el crecimiento de ingresos.

Netcapital Inc. (나스닥: NCPL)는 2025년 6월 26일 스위스에 본사를 둔 Horizon Globex GmbH와 Horizon 소프트웨어 계약을 체결했다고 8-K 보고서를 제출했습니다. Horizon은 Netcapital에 미국 내 자사 브랜드로 Horizon의 자본 조달 및 2차 거래 소프트웨어를 사용할 수 있는 로열티 없는, 완납된, 비독점적이며 영구적이고 취소 불가능한 라이선스를 부여했습니다.

대가로 Netcapital은 Horizon 또는 그 계열사에 500,000주의 보통주(“Horizon 주식”)를 발행할 예정입니다. 이 주식은 증권법 섹션 4(a)(2) 및/또는 3(a)(9)에 따라 등록 없이 발행되며, 회사는 현금을 받지 않습니다.

계약에는 표준 해지 권리가 포함되어 있습니다: (i) 어느 쪽 당사자든 중대한 위반 시 30일간의 시정 기간 후 해지할 수 있으며, (ii) 상대방이 파산, 수탁자 지정, 해산 또는 사업 중단 시 즉시 해지가 가능합니다. 전체 계약서는 부록 10.1로 첨부되어 있습니다.

이번 거래를 통해 Netcapital은 장기적으로 거래 기술 플랫폼에 접근할 수 있게 되어 서비스 제공 범위를 확대할 수 있으나, 지분 희석과 소프트웨어가 수익 성장을 견인하지 못할 경우 실행 위험도 수반합니다.

Netcapital Inc. (Nasdaq : NCPL) a déposé un 8-K indiquant que le 26 juin 2025, elle a conclu un Contrat logiciel Horizon avec Horizon Globex GmbH, basée en Suisse. Horizon a accordé à Netcapital une licence perpétuelle, irrévocable, non exclusive, sans redevance et entièrement acquittée pour utiliser le logiciel de levée de fonds et de trading secondaire d’Horizon sous la marque de la société aux États-Unis.

En contrepartie, Netcapital émettra 500 000 actions ordinaires (les « Actions Horizon ») à Horizon ou à une de ses affiliées. Les actions seront émises sans enregistrement en vertu des sections 4(a)(2) et/ou 3(a)(9) du Securities Act, et aucun paiement en espèces ne sera reçu par la société.

Le contrat inclut des droits de résiliation standards : (i) chaque partie peut résilier après un délai de 30 jours pour remédier à une violation substantielle, et (ii) une résiliation immédiate est possible en cas de faillite, de mise sous séquestre, de dissolution ou de cessation d’activité de l’autre partie. Le contrat complet est joint en Annexe 10.1.

Cette opération offre à Netcapital un accès à long terme à une plateforme technologique de trading qui pourrait élargir son offre de services, mais elle introduit également une dilution des actions et un risque d’exécution si le logiciel ne génère pas de croissance des revenus.

Netcapital Inc. (Nasdaq: NCPL) hat einen 8-K eingereicht, in dem berichtet wird, dass am 26. Juni 2025 ein Horizon Softwarevertrag mit der in der Schweiz ansässigen Horizon Globex GmbH abgeschlossen wurde. Horizon gewährte Netcapital eine lizenzgebührenfreie, abgegoltene, nicht-exklusive, unbefristete und unwiderrufliche Lizenz zur Nutzung von Horizons Kapitalbeschaffungs- und Sekundärhandelssoftware unter der eigenen Marke des Unternehmens in den Vereinigten Staaten.

Als Gegenleistung wird Netcapital 500.000 Stammaktien („Horizon-Aktien“) an Horizon oder eine verbundene Gesellschaft ausgeben. Die Aktien werden ohne Registrierung gemäß den Abschnitten 4(a)(2) und/oder 3(a)(9) des Securities Act ausgegeben, und es wird kein Bargeld von der Gesellschaft erhalten.

Der Vertrag enthält Standardkündigungsrechte: (i) jede Partei kann nach einer 30-tägigen Nachbesserungsfrist bei wesentlicher Vertragsverletzung kündigen, und (ii) eine sofortige Kündigung ist bei Insolvenz, Zwangsverwaltung, Auflösung oder Geschäftsaufgabe der anderen Partei zulässig. Der vollständige Vertrag ist als Anlage 10.1 beigefügt.

Diese Transaktion verschafft Netcapital langfristigen Zugang zu einer Trading-Technologieplattform, die das Dienstleistungsangebot erweitern könnte, bringt jedoch auch Aktienverwässerung und Ausführungsrisiken mit sich, falls die Software das Umsatzwachstum nicht fördert.

Positive
  • Perpetual, royalty-free software license could lower operating costs and enhance Netcapital’s product suite.
  • No cash consideration preserves the Company’s balance-sheet liquidity.
Negative
  • Equity dilution from issuing 500,0000 new shares without cash inflow.
  • Lack of disclosed revenue projections or milestones makes the economic benefit uncertain.

Insights

TL;DR Strategic software access is positive, but unknown value versus dilution keeps impact neutral-to-slightly positive.

The perpetual, royalty-free license removes ongoing cost burdens and could accelerate Netcapital’s expansion in digital capital-raising and secondary trading services. Assuming the reported 500,0000 shares equal roughly 6-7 % of outstanding shares (management has not disclosed exact share count here), immediate dilution is modest and cash-less, helping conserve liquidity. However, the filing lacks revenue projections, integration timelines, or client commitments, making it impossible to quantify upside. Overall, the deal broadens capabilities with limited cash outlay, but its economic impact will hinge on user adoption and competitive differentiation.

TL;DR Deal structure is standard; shareholder dilution and vague performance metrics temper enthusiasm.

The software license is perpetual and non-exclusive, protecting Netcapital’s long-term access even if Horizon changes ownership. Termination clauses mirror industry norms, providing 30-day cure periods and bankruptcy triggers. Yet the issuance of unregistered shares raises governance questions: (i) the precise size of the equity grant is ambiguous due to the extra zero in “500,0000”; (ii) shareholders receive no disclosure on valuation methodology. Without a performance-based share-vesting schedule or milestones, shareholders bear dilution risk without contractual assurance of value delivery. Governance impact is therefore mixed.

Netcapital Inc. (Nasdaq: NCPL) ha depositato un 8-K comunicando che il 26 giugno 2025 ha stipulato un Accordo Software Horizon con la società svizzera Horizon Globex GmbH. Horizon ha concesso a Netcapital una licenza perpetua, irrevocabile, non esclusiva, royalty-free e completamente pagata per utilizzare il software di raccolta capitali e trading secondario di Horizon con il proprio marchio negli Stati Uniti.

In cambio, Netcapital emetterà 500.000 azioni ordinarie (le “Azioni Horizon”) a favore di Horizon o di una sua affiliata. Le azioni saranno emesse senza registrazione ai sensi delle Sezioni 4(a)(2) e/o 3(a)(9) del Securities Act, e la Società non riceverà alcun pagamento in contanti.

L’accordo prevede diritti di risoluzione standard: (i) ciascuna parte può recedere dopo un periodo di 30 giorni per sanare una violazione sostanziale, e (ii) la risoluzione immediata è consentita in caso di bancarotta, amministrazione controllata, scioglimento o cessazione dell’attività dell’altra parte. Il contratto completo è allegato come Allegato 10.1.

Questa operazione garantisce a Netcapital un accesso a lungo termine a una piattaforma tecnologica di trading che potrebbe ampliare la gamma di servizi offerti, ma comporta anche un diluzione azionaria e un rischio di esecuzione nel caso in cui il software non generi crescita dei ricavi.

Netcapital Inc. (Nasdaq: NCPL) presentó un 8-K informando que el 26 de junio de 2025 firmó un Acuerdo de Software Horizon con Horizon Globex GmbH, con sede en Suiza. Horizon otorgó a Netcapital una licencia perpetua, irrevocable, no exclusiva, libre de regalías y totalmente pagada para usar el software de captación de capital y comercio secundario de Horizon bajo la marca de la Compañía en Estados Unidos.

Como contraprestación, Netcapital emitirá 500,000 acciones ordinarias (las “Acciones Horizon”) a Horizon o a una afiliada. Las acciones se emitirán sin registro conforme a las Secciones 4(a)(2) y/o 3(a)(9) de la Ley de Valores, y la Compañía no recibirá efectivo.

El acuerdo incluye derechos estándar de terminación: (i) cualquiera de las partes puede rescindir tras un período de subsanación de 30 días por incumplimiento material, y (ii) se permite la terminación inmediata en caso de quiebra, administración judicial, disolución o cese de operaciones de la otra parte. El contrato completo se adjunta como Anexo 10.1.

Esta transacción le otorga a Netcapital acceso a largo plazo a una plataforma tecnológica de trading que podría ampliar su oferta de servicios, pero también implica dilución accionaria y riesgo de ejecución si el software no impulsa el crecimiento de ingresos.

Netcapital Inc. (나스닥: NCPL)는 2025년 6월 26일 스위스에 본사를 둔 Horizon Globex GmbH와 Horizon 소프트웨어 계약을 체결했다고 8-K 보고서를 제출했습니다. Horizon은 Netcapital에 미국 내 자사 브랜드로 Horizon의 자본 조달 및 2차 거래 소프트웨어를 사용할 수 있는 로열티 없는, 완납된, 비독점적이며 영구적이고 취소 불가능한 라이선스를 부여했습니다.

대가로 Netcapital은 Horizon 또는 그 계열사에 500,000주의 보통주(“Horizon 주식”)를 발행할 예정입니다. 이 주식은 증권법 섹션 4(a)(2) 및/또는 3(a)(9)에 따라 등록 없이 발행되며, 회사는 현금을 받지 않습니다.

계약에는 표준 해지 권리가 포함되어 있습니다: (i) 어느 쪽 당사자든 중대한 위반 시 30일간의 시정 기간 후 해지할 수 있으며, (ii) 상대방이 파산, 수탁자 지정, 해산 또는 사업 중단 시 즉시 해지가 가능합니다. 전체 계약서는 부록 10.1로 첨부되어 있습니다.

이번 거래를 통해 Netcapital은 장기적으로 거래 기술 플랫폼에 접근할 수 있게 되어 서비스 제공 범위를 확대할 수 있으나, 지분 희석과 소프트웨어가 수익 성장을 견인하지 못할 경우 실행 위험도 수반합니다.

Netcapital Inc. (Nasdaq : NCPL) a déposé un 8-K indiquant que le 26 juin 2025, elle a conclu un Contrat logiciel Horizon avec Horizon Globex GmbH, basée en Suisse. Horizon a accordé à Netcapital une licence perpétuelle, irrévocable, non exclusive, sans redevance et entièrement acquittée pour utiliser le logiciel de levée de fonds et de trading secondaire d’Horizon sous la marque de la société aux États-Unis.

En contrepartie, Netcapital émettra 500 000 actions ordinaires (les « Actions Horizon ») à Horizon ou à une de ses affiliées. Les actions seront émises sans enregistrement en vertu des sections 4(a)(2) et/ou 3(a)(9) du Securities Act, et aucun paiement en espèces ne sera reçu par la société.

Le contrat inclut des droits de résiliation standards : (i) chaque partie peut résilier après un délai de 30 jours pour remédier à une violation substantielle, et (ii) une résiliation immédiate est possible en cas de faillite, de mise sous séquestre, de dissolution ou de cessation d’activité de l’autre partie. Le contrat complet est joint en Annexe 10.1.

Cette opération offre à Netcapital un accès à long terme à une plateforme technologique de trading qui pourrait élargir son offre de services, mais elle introduit également une dilution des actions et un risque d’exécution si le logiciel ne génère pas de croissance des revenus.

Netcapital Inc. (Nasdaq: NCPL) hat einen 8-K eingereicht, in dem berichtet wird, dass am 26. Juni 2025 ein Horizon Softwarevertrag mit der in der Schweiz ansässigen Horizon Globex GmbH abgeschlossen wurde. Horizon gewährte Netcapital eine lizenzgebührenfreie, abgegoltene, nicht-exklusive, unbefristete und unwiderrufliche Lizenz zur Nutzung von Horizons Kapitalbeschaffungs- und Sekundärhandelssoftware unter der eigenen Marke des Unternehmens in den Vereinigten Staaten.

Als Gegenleistung wird Netcapital 500.000 Stammaktien („Horizon-Aktien“) an Horizon oder eine verbundene Gesellschaft ausgeben. Die Aktien werden ohne Registrierung gemäß den Abschnitten 4(a)(2) und/oder 3(a)(9) des Securities Act ausgegeben, und es wird kein Bargeld von der Gesellschaft erhalten.

Der Vertrag enthält Standardkündigungsrechte: (i) jede Partei kann nach einer 30-tägigen Nachbesserungsfrist bei wesentlicher Vertragsverletzung kündigen, und (ii) eine sofortige Kündigung ist bei Insolvenz, Zwangsverwaltung, Auflösung oder Geschäftsaufgabe der anderen Partei zulässig. Der vollständige Vertrag ist als Anlage 10.1 beigefügt.

Diese Transaktion verschafft Netcapital langfristigen Zugang zu einer Trading-Technologieplattform, die das Dienstleistungsangebot erweitern könnte, bringt jedoch auch Aktienverwässerung und Ausführungsrisiken mit sich, falls die Software das Umsatzwachstum nicht fördert.

false 0001711754 0001711754 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2025

 

INMUNE BIO INC.
(Exact name of registrant as specified in charter)

 

Nevada   001-38793   47-5205835
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)

 

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

 

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per shares   INMB   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

  

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On June 27, 2025, INmune Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of common stock, par value $0.001 per share (the “Shares”), in a registered direct offering (the “Offering”) at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds to the Company of approximately $18.9 million, before deducting placement agent fees and expenses.

 

The Shares were offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279036), declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 7, 2024, and a prospectus supplement filed with the SEC on June 30, 2025. The Offering closed on June 30, 2025.

 

A.G.P./Alliance Global Partners acted as the sole placement agent for the Offering pursuant to a Placement Agency Agreement dated June 27, 2025 (the “Placement Agency Agreement”). The Company agreed to pay the placement agent a cash fee equal to 7.0% of the gross proceeds and to reimburse certain legal and other expenses.

 

Sichenzia Ross Reference Carmel LLP, counsel to the Company, has issued an opinion to the Company regarding the validity of the securities to be issued in the Offering. A copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K.

 

The foregoing summaries of the Purchase Agreement and the Placement Agency Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.

 

Item 8.01. Other Events.

 

On June 27, 2025, the Company issued a press release announcing the pricing of the Offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Form 8-K.

 

On June 30, 2025, the Company issued a press release announcing the closing of the Offering, a copy of which is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01 of this Form 8-K.

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

5.1   Opinion of Sichenzia Ross Ference Carmel LLP
10.1   Form of Securities Purchase Agreement, dated June 27, 2025
10.2   Form of Placement Agency Agreement, dated June 27, 2025
23.1   Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)
99.1   Press Release, dated June 27, 2025
99.2   Press Release, dated June 30, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMUNE BIO INC.
   
Date: June 30, 2025 By: /s/ David Moss
    David Moss
    Chief Financial Officer

 

 

2

 

FAQ

What did Netcapital (NCPL) announce in its June 26 2025 8-K?

It entered into a Horizon Software Agreement, gaining a perpetual license to Horizon’s capital-raising and trading software in exchange for 500,0000 NCPL shares.

How many shares is Netcapital issuing to Horizon Globex?

The filing states an issuance of 500,0000 common shares, exempt from registration under Sections 4(a)(2)/3(a)(9).

Will Netcapital receive cash for the share issuance?

No. The Horizon Shares are being issued as non-cash consideration for the software license.

Can the Horizon Software Agreement be terminated?

Yes. Either party may terminate for uncured material breach after 30 days, or immediately upon bankruptcy-related events.

Why is the agreement potentially important for investors?

It could broaden Netcapital’s service offerings and revenue sources, but also introduces dilution and execution risk.
Inmune Bio Inc

NASDAQ:INMB

INMB Rankings

INMB Latest News

INMB Latest SEC Filings

INMB Stock Data

172.31M
16.63M
23.96%
23.87%
24.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOCA RATON